Valuation: Aligos Therapeutics, Inc.

Market Cap 33.6M 29.82M 27.91M 25.3M 47.77M 3.24B 48.12M 335M 130M 1.65B 126M 123M 5.31B P/E 2026 *
-0.83x
P/E 2027 * -1x
Enterprise Value -10.28K -9.12K -8.54K -7.74K -14.62K -991K -14.72K -103K -39.88K -505K -38.58K -37.75K -1.62M EV / Sales 2026 *
-
EV / Sales 2027 * -56.9x
Free-Float
77.91%
Yield 2026 *
-
Yield 2027 * -
1 day-0.37%
1 week-4.27%
Current month-4.44%
1 month-13.37%
3 months-8.03%
6 months-33.50%
Current year-42.27%
1 week 5.31
Extreme 5.3103
5.74
1 month 4.82
Extreme 4.82
6.34
Current year 3.98
Extreme 3.98
10.49
1 year 3.98
Extreme 3.98
13.69
3 years 3.76
Extreme 3.76
46.8
5 years 3.76
Extreme 3.76
449.25
10 years 3.76
Extreme 3.76
937.75
Manager TitleAgeSince
Chief Executive Officer 64 04/02/2018
Director of Finance/CFO 60 31/05/2020
Chief Tech/Sci/R&D Officer 65 30/04/2018
Director TitleAgeSince
Director/Board Member 64 31/07/2018
Director/Board Member 74 31/07/2018
Chairman 64 -
Date Insider Type Main position Quantity % Market Cap. Importance
09/03/26 Free

Chief Technology Officer

23,310 0.4354%
09/03/26 Free

Controller/Auditor

9,450 0.1765%
09/03/26 Free

Chief Executive Officer

105,840 1.9770%
Change 5-day change 1-year change 3-year change Capi.($)
-0.37%-4.27%-47.36%-72.02% 33.72M
+4.16%+4.16%+49.37%+94.17% 74.31B
+2.76%-1.60%+22.80%+78.53% 56.95B
+0.24%-1.34%+3.41%+34.31% 48.3B
-3.76%-2.25%+329.09%+698.20% 44.51B
-2.30%-3.35%+26.81%+30.88% 43.8B
+0.31%-0.68%+5.30%+108.64% 41.12B
-0.11%+1.96%+9.19%+52.66% 31.07B
-1.99%+1.25%+35.12%+26.39% 28.97B
-1.96%-2.88%-8.97%-13.92% 24.53B
Average -0.30%-1.13%+42.48%+103.79% 39.36B
Weighted average by Cap. +0.29%-0.94%+56.54%+132.33%

Financials

2026 *2027 *
Net sales 35.99M 31.95M 29.9M 27.1M 51.18M 3.47B 51.55M 359M 140M 1.77B 135M 132M 5.69B 4.65M 4.13M 3.86M 3.5M 6.61M 448M 6.66M 46.39M 18.04M 229M 17.45M 17.08M 735M
Net income -79.34M -70.43M -65.91M -59.74M -113M -7.65B -114M -792M -308M -3.9B -298M -291M -12.54B -125M -111M -104M -94.04M -178M -12.04B -179M -1.25B -485M -6.14B -469M -459M -19.74B
Net Debt -33.61M -29.83M -27.92M -25.3M -47.79M -3.24B -48.13M -335M -130M -1.65B -126M -123M -5.31B -298M -265M -248M -225M -424M -28.74B -427M -2.98B -1.16B -14.66B -1.12B -1.1B -47.14B
Projected Income Statement - Annual - Aligos Therapeutics, Inc.
Logo Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Employees
82
Date Price Change Volume
06/10/26 US$5.380 -0.37% 12,841
05/10/26 US$5.400 -2.53% 48,608
02/10/26 US$5.540 +0.73% 29,035
01/10/26 US$5.500 -2.31% 28,258
30/09/26 US$5.630 +0.18% 35,330
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Aligos Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.380USD
Average target price
52.38USD
Spread / Average Target
+873.51%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Aligos Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ALGS Stock